Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study co-led by the University of Oxford and University of Birmingham, published in Lancet Oncology today by the UK Coronavirus Cancer Monitoring Project (UKCCMP), found that blood cancer patients were particularly at risk with 57% higher odds of severe disease if they contract COVID-19. This was when compared to other cancer patients, such as breast cancer, which was shown to have the lowest risk overall.

coronavirus cell © Alissa Eckert, MS; Dan Higgins, MAM

In line with what we already know about the coronavirus pandemic, age was shown to play a factor in the overall outcome, with cancer patients over the age of 80 found to have the highest frequency of fatality. As access to treatment remains of upmost importance, this information will help clinicians to guide patients to ensure they can have therapy safely and successfully during this time.

When COVID-19 spread globally in early 2020, cancer patients were identified as a sub-group who were potentially at an increased risk of infection of COVID-19 and of potentially suffering more serious disease consequences. It was this concern that led to the formation of the national UKCCMP project.

As cancer treatments need to carry on during the pandemic, this study gives clinicians and patients important information to make informed decisions about that treatment. The production of risk tables for different cancer types will let doctors discuss the risks and benefits with patients, so that together they can pick the best way to treat each person’s cancer. The study also gives an evidence base from which hospitals and other healthcare providers can design measures to ensure that they maintain access to life-saving treatments as safely as possible.

The full story is available on the Cancer Research UK Oxford centre website

This story is also featured on the University of Oxford website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.